{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:54:32Z","timestamp":1771653272479,"version":"3.50.1"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejpn.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T01:58:39Z","timestamp":1640829519000},"page":"159-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders"],"prefix":"10.1016","volume":"36","author":[{"given":"Nina","family":"Bari\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Turudi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna Stemberger","family":"Mari\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Te\u0161ovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejpn.2021.12.014_bib1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/nm1097-1133","article-title":"Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading","volume":"3","author":"Miller","year":"1997","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib3","first-page":"121","article-title":"ASIA-autoimmune syndromes induced by adjuvants: rare, but worth considering","volume":"14","author":"Toubi","year":"2012","journal-title":"Isr. Med. Assoc. J."},{"issue":"31","key":"10.1016\/j.ejpn.2021.12.014_bib4","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.vaccine.2019.06.039","article-title":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines","volume":"37","author":"Hauser","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ejpn.2021.12.014_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.autrev.2011.10.007","article-title":"The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity","volume":"11","author":"Nahum","year":"2012","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.ejpn.2021.12.014_bib6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrrheum.2009.196","article-title":"Vaccines and autoimmunity","volume":"5","author":"Agmon-Levin","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/mus.27224","article-title":"Influenza vaccination in autoimmune neuromuscular diseas-es: a survey of current practices and perceptions","volume":"63","author":"Roy","year":"2021","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.ejpn.2021.12.014_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-019-00670-y","article-title":"Do vaccines trigger neurological diseases? Epidemiological evaluation of vaccination and neurological diseases using examples of multiple sclerosis, guillain-barr\u00e9 syndrome and narcolepsy","volume":"34","author":"Stowe","year":"2020","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib11","first-page":"348","article-title":"Developing clinical guidelines","volume":"170","author":"Shekelle","year":"1999","journal-title":"West. J. Med."},{"key":"10.1016\/j.ejpn.2021.12.014_bib12","author":"Oxford Centre for Evidence-Based Medicine"},{"issue":"2 Suppl","key":"10.1016\/j.ejpn.2021.12.014_bib14","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1378\/chest.95.2_Supplement.2S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents","volume":"95","author":"Sackett","year":"1989","journal-title":"Chest"},{"issue":"4 Suppl","key":"10.1016\/j.ejpn.2021.12.014_bib15","first-page":"305S","article-title":"Rules of evidence and clinical recommendations on the use of antithrombotic agents","volume":"102","author":"Cook","year":"1992","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1016\/j.ejpn.2021.12.014_bib16","first-page":"ii9","article-title":"Management of inflammatory neuropathies","volume":"74","author":"Hadden","year":"2003","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review","volume":"32","author":"McGrogan","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jpids\/piaa086","article-title":"Guillain-barr\u00e9 syndrome associated with severe acute respiratory syndrome coronavirus 2 detection and coronavirus disease 2019 in a Child","volume":"17;9","author":"Khalifa","year":"2020","journal-title":"J.\u00a0Pediatr. Infect. Dis. Soc."},{"issue":"11","key":"10.1016\/j.ejpn.2021.12.014_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2021.12.014_bib21","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2021.12.014_bib22","series-title":"Guillain- Barr\u00e9 Syndrome Ch. 12","first-page":"155","author":"Ropper","year":"1991"},{"key":"10.1016\/j.ejpn.2021.12.014_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clineuro.2017.05.006","article-title":"Guillain-Barr\u00e9 Syndrome, variants & forms fruste: reclassification with new criteria","volume":"158","author":"Hiew","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10072-019-04156-z","article-title":"Guillain-Barr\u00e9 syndrome and antecedent cytomegalovirus infection, USA 2009-2015","volume":"41","author":"Leung","year":"2020","journal-title":"Neurol Sci."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"issue":"9707","key":"10.1016\/j.ejpn.2021.12.014_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"19","author":"Black","year":"2009","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.ejpn.2021.12.014_bib27","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barr\u00e9 syndrome and influenza vaccines: a meta-analysis","volume":"33","author":"Mart\u00edn Arias","year":"2015","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-barre syndrome following vaccination in the national influenza immuni-zation program, United States, 1976--1977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/oxfordjournals.aje.a113809","article-title":"An epidemiologic and clinical evaluation of Guillain-Barr\u00e9 syndrome reported in association with the administration of swine influenza vaccines","volume":"119","author":"Langmuir","year":"1984","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib32","series-title":"Immunization Safety Review Committee. Immunization Safety Review: Influenza Vaccines and Neurological Complications","year":"2004"},{"issue":"15","key":"10.1016\/j.ejpn.2021.12.014_bib33","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.vaccine.2015.02.035","article-title":"Pandemic influenza A vaccination and incidence of Guillain-Barr\u00e9 syndrome in Korea","volume":"33","author":"Kim","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","article-title":"Risk of Guillain-Barr\u00e9 syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study","volume":"31","author":"Ghaderi","year":"2016","journal-title":"Eur. J. Epidemiol."},{"issue":"40","key":"10.1016\/j.ejpn.2021.12.014_bib35","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","article-title":"International collaboration to assess the risk of Guillain Barr\u00e9 Syndrome following Influenza A (H1N1) 2009 monovalent vaccines","volume":"31","author":"Dodd","year":"2013","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.ejpn.2021.12.014_bib36","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the vaccine adverse event reporting system (VAERS) for anaphylaxis and for guillain-barr\u00e9 syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ejpn.2021.12.014_bib37","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the post-licensure rapid immunization safety monitoring (PRISM) system, 2009-2010","volume":"175","author":"Yih","year":"2012","journal-title":"Am. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib38","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/1744666X.2013.824686","article-title":"Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barr\u00e9 syndrome?","volume":"9","author":"Salmon","year":"2013","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"37","key":"10.1016\/j.ejpn.2021.12.014_bib39","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1016\/j.vaccine.2018.05.119","article-title":"Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome","volume":"37","author":"Principi","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/archdischild-2013-304475","article-title":"Pandemic A\/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barr\u00e9 syndrome","volume":"99","author":"Verity","year":"2014","journal-title":"Arch. Dis. Child."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and guillain-barr\u00e9 syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejpn.2021.12.014_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12865-014-0061-0","article-title":"In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseases","volume":"15","author":"McGarvey","year":"2014","journal-title":"BMC Immunol."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.73.3.348","article-title":"Risk of relapse of Guillain-Barr\u00e9 syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation","volume":"73","author":"Pritchard","year":"2002","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0002-9343(76)90762-2","article-title":"Guillain-Barr\u00e9 syndrome following administration of live measles vaccine","volume":"60","author":"Grose","year":"1976","journal-title":"Am. J. Med."},{"issue":"8888","key":"10.1016\/j.ejpn.2021.12.014_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(94)90917-2","article-title":"Guillain-Barr\u00e9 syndrome after measles, mumps, and rubella vaccine","volume":"343","author":"Morris","year":"1994","journal-title":"Lancet"},{"issue":"9044","key":"10.1016\/j.ejpn.2021.12.014_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(96)07408-9","article-title":"Measles vaccination and Guillain-Barr\u00e9 syndrome","volume":"349","author":"da Silveira","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barr\u00e9 syndrome after measles-mumps-rubella vaccination","volume":"138","author":"Patja","year":"2001","journal-title":"J.\u00a0Pediatr."},{"issue":"Suppl 1","key":"10.1016\/j.ejpn.2021.12.014_bib48","first-page":"S223","article-title":"Measles-rubella mass immunization campaign in Albania","volume":"187","author":"Bino","year":"2000","journal-title":"J.\u00a0Infect. Dis."},{"issue":"39","key":"10.1016\/j.ejpn.2021.12.014_bib49","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1016\/j.vaccine.2008.07.014","article-title":"Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children","volume":"26","author":"Esteghamati","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib50","first-page":"1124","article-title":"Guillain - barre' syndrome following recombinant hepatitis B vaccine and literature review","volume":"83","author":"Sinsawaiwong","year":"2000","journal-title":"J.\u00a0Med. Assoc. Thai."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2021.12.014_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2010.02.016","article-title":"Neuromuscular disorders associated with Hepatitis B vaccination","volume":"292","author":"St\u00fcbgen","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"36","key":"10.1016\/j.ejpn.2021.12.014_bib52","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpn.2021.12.014_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2017.01.005","article-title":"Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: six years of case-referent surveillance","volume":"79","author":"Grimaldi-Bensouda","year":"2017","journal-title":"J.\u00a0Autoimmun."},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2021.12.014_bib54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jns.2010.09.015","article-title":"Neuromuscular complications of hepatitis A virus infection and vaccines","volume":"300","author":"St\u00fcbgen","year":"2011","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/01.inf.0000130941.72712.33","article-title":"Possible association of Guillain-Barr\u00e9 syndrome and hepatitis A vaccination","volume":"23","author":"Blumenthal","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"8660","key":"10.1016\/j.ejpn.2021.12.014_bib56","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0140-6736(89)90609-0","article-title":"Cluster of childhood Guillain-Barr\u00e9 cases after an oral poliovaccine campaign","volume":"2","author":"Uhari","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10654-019-00596-1","article-title":"Vaccines and the risk of Guillain-Barr\u00e9 syndrome","volume":"35","author":"Chen","year":"2020","journal-title":"Eur. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.ejpn.2021.12.014_bib58","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2105\/AJPH.87.12.2045","article-title":"The risk of Guillain-Barr\u00e9 syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States","volume":"87","author":"Tuttle","year":"1997","journal-title":"Am. J. Publ. Health"},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib59","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/WNL.39.8.1034","article-title":"Incidence of Guillain-Barr\u00e9 syndrome during a nationwide oral poliovirus vaccine campaign","volume":"39","author":"Kinnunen","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/oxfordjournals.aje.a009369","article-title":"Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barr\u00e9 Syndrome","volume":"147","author":"Kinnunen","year":"1998","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib61","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-3476(94)70307-8","article-title":"Epidemiology of Guillain-Barr\u00e9 syndrome in children: relationship of oral polio vaccine administration to occurrence","volume":"124","author":"Rantala","year":"1994","journal-title":"J.\u00a0Pediatr."},{"issue":"40","key":"10.1016\/j.ejpn.2021.12.014_bib62","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.vaccine.2020.07.039","article-title":"Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra) reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"38","author":"Myers","year":"2005","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.ejpn.2021.12.014_bib63","first-page":"1023","article-title":"Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"13","key":"10.1016\/j.ejpn.2021.12.014_bib64","first-page":"364","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006","volume":"55","author":"Centers for Disease Control and Prevention (CDC)","year":"2006","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib65","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1086\/533469","article-title":"Risk of Guillain-Barr\u00e9 syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada","volume":"46","author":"De Wals","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 5","key":"10.1016\/j.ejpn.2021.12.014_bib66","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1016\/j.vaccine.2015.10.080","article-title":"The safety of influenza vaccines in children: an Institute for Vaccine Safety white paper","volume":"33","author":"Halsey","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0002-9343(92)90073-K","article-title":"Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons","volume":"92","author":"McMahon","year":"1992","journal-title":"Am. J. Med."},{"issue":"13","key":"10.1016\/j.ejpn.2021.12.014_bib69","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib70","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barr\u00e9 syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am. J. Publ. Health"},{"key":"10.1016\/j.ejpn.2021.12.014_bib71","series-title":"Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality","year":"1994"},{"key":"10.1016\/j.ejpn.2021.12.014_bib72","series-title":"Adverse Effects of Vaccines: Evidence and Causality","year":"2012"},{"issue":"7","key":"10.1016\/j.ejpn.2021.12.014_bib73","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF01954093","article-title":"Guillain-Barr\u00e9 syndrome following immunisation with Haemophilus influenzae type b conjugate vaccine","volume":"152","author":"Gervaix","year":"1993","journal-title":"Eur. J. Pediatr."},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib74","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0929-693X(01)00547-4","article-title":"Syndrome de Guillain-Barr\u00e9 apr\u00e8s vaccination contre Haemophilus influenzae type b [Guillain-Barre syndrome following immunization against Haemophilus influenzae type b]","volume":"8","author":"Nejmi","year":"2001","journal-title":"Arch. Pediatr."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0022-3476(05)81786-X","article-title":"Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine","volume":"121","author":"Fritzell","year":"1992","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ejpn.2021.12.014_bib76","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib77","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2021.12.014_bib78","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp-2020-324491","article-title":"Guillain-Barr\u00e9 syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic","volume":"91","author":"BC","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib79","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jpids\/piaa086","article-title":"Guillain-barr\u00e9 syndrome associated with severe acute respiratory syndrome coronavirus 2 detection and coronavirus disease 2019 in a Child","volume":"9","author":"Khalifa","year":"2020","journal-title":"J.\u00a0Pediatr. Infect. Dis. Soc."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.27179","article-title":"Doctor \u2013 should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders","volume":"63","author":"\u017divkovi\u0107","year":"2021","journal-title":"Muscle Nerve Muscle Nerve"},{"issue":"47","key":"10.1016\/j.ejpn.2021.12.014_bib82","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.15585\/mmwr.mm6947e3","article-title":"The advisory committee on immunization practices' ethical principles for allocating initial supplies of COVID-19 vaccine - United States, 2020","volume":"69","author":"McClung","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"49","key":"10.1016\/j.ejpn.2021.12.014_bib83","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.15585\/mmwr.mm6949e1","article-title":"The advisory committee on immunization practices' interim recommendation for allocating initial supplies of COVID-19 vaccine - United States, 2020","volume":"69","author":"Dooling","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib84","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/cir960","article-title":"Recurrent Guillain-Barre syndrome following vaccination","volume":"54","author":"Baxter","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib85","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.ejpn.2021.12.014_bib86","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2014-308452","article-title":"Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Kuwabara","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib87","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CND.0000000000000179","article-title":"Pediatric CIDP: clinical features and response to treatment","volume":"19","author":"Harada","year":"2017","journal-title":"J.\u00a0Clin. Neuromuscul. Dis."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib89","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejpn.2011.12.003","article-title":"Childhood chronic inflammatory demyelinating polyneuroradiculopathy--three cases and a review of the literature","volume":"16","author":"Riekhoff","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib90","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nmd.2018.06.001","article-title":"Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Silwal","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1529-8027.2009.00243.x","article-title":"Recurrences, vaccinations and long-term symptoms in GBS and CIDP","volume":"14","author":"Kuitwaard","year":"2009","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpn.2008.04.009","article-title":"Childhood acute and chronic immune-mediated polyradiculoneuropathies","volume":"13","author":"Rabie","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jns.12435","article-title":"Acute and chronic inflammatory neuropathies and COVID-19 vaccines: practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)","volume":"26","author":"Doneddu","year":"2021","journal-title":"J.\u00a0Peripher. Nerv. Syst."},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib94","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.vaccine.2011.11.109","article-title":"Are immunosuppressive medications associated with decreased responses to routine immunizations? a systematic review","volume":"30","author":"Agarwal","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ejpn.2021.12.014_bib95","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/jnnp-2014-309563","article-title":"Bell's palsy: aetiology, clinical features and multidisciplinary care","volume":"86","author":"Eviston","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"13","key":"10.1016\/j.ejpn.2021.12.014_bib96","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMcp041120","article-title":"Clinical practice. Bell's Palsy","volume":"351","author":"Gilden","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib97","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and Bell's palsy in children: a case-centered analysis","volume":"175","author":"Rowhani-Rahbar","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000338303","article-title":"Epidemiologic and clinical features of Bell's palsy among children in northern California","volume":"38","author":"Rowhani-Rahbar","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2007.10.043","article-title":"All that palsies is not Bell's - the need to define Bell's palsy as an adverse event following immunization","volume":"26","author":"Rath","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pds.998","article-title":"A\u00a0potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001","volume":"13","author":"Zhou","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"Vaccine Safety Datalink Project. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.ejpn.2021.12.014_bib102","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ejpn.2021.12.014_bib104","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.autrev.2013.03.012","article-title":"A\u00a0literature review on optic neuritis following vaccination against virus infections","volume":"12","author":"St\u00fcbgen","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/bjophthalmol-2018-312399","article-title":"Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China","volume":"103","author":"Song","year":"2019","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.ejpn.2021.12.014_bib106","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2021.12.014_bib107","first-page":"86","article-title":"High association of MOG-IgG antibodies in children with bilateral optic neuritis","volume":"27","author":"Wendel","year":"2020","journal-title":"EJPN"},{"key":"10.1016\/j.ejpn.2021.12.014_bib108","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/0883073809349322","article-title":"A\u00a016-year-old girl with bilateral visual loss and left hemiparesisfollowing an immunization against human papilloma virus","volume":"25","author":"Di Mario","year":"2010","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib109","first-page":"594","article-title":"Optic neuritis following hepatitis B vaccination in a 9-year-old girl","volume":"72","author":"Erguven","year":"2009","journal-title":"J.\u00a0Clin. Med. Assoc."},{"key":"10.1016\/j.ejpn.2021.12.014_bib110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/INF.0b013e3181f11126","article-title":"Adverse neurologic reactions after both doses of pandemicH1N1 influenza vaccine, with optic neuritis and demyelination","volume":"30","author":"Lapphra","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"48","key":"10.1016\/j.ejpn.2021.12.014_bib111","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1016\/j.vaccine.2014.09.053","article-title":"Elevated serum anti-phosphatidylcholine IgG antibodies in patients with influenza vaccination-associated optic neuritis","volume":"32","author":"Korematsu","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cid\/ciw224","article-title":"Case-centered analysis of optic neuritis after vaccines","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ejpn.2021.12.014_bib113","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/21645515.2017.1310788","article-title":"Evaluation of optic neuritis following human papillomavirus vaccination","volume":"13","author":"Sridhar","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib114","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.spen.2017.04.003","article-title":"Pediatric myasthenia gravis","volume":"24","author":"Peragallo","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."},{"issue":"20","key":"10.1016\/j.ejpn.2021.12.014_bib116","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib117","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.25267","article-title":"Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis","volume":"84","author":"He","year":"2018","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib118","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J.\u00a0Clin. Neurol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ebiom.2018.01.007","article-title":"Acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with myasthenia gravis: a double-blind randomized controlled trial (ProPATIent-Trial)","volume":"28","author":"Tackenberg","year":"2018","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib120","first-page":"1251","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J.\u00a0Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2021.12.014_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029249","article-title":"Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective","volume":"6","author":"Beck","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejpn.2021.12.014_bib122","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A\u00a0prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ejpn.2021.12.014_bib123","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.ejpn.2021.12.014_bib124","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.dld.2017.09.002","article-title":"Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients","volume":"49","author":"Abreu","year":"2017","journal-title":"Dig. Liver Dis."},{"issue":"45","key":"10.1016\/j.ejpn.2021.12.014_bib125","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1016\/j.vaccine.2014.09.003","article-title":"Vaccination recommendations for patients with neuromuscular disease","volume":"32","author":"Esposito","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib126","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"Nternational consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib127","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jpids\/piz058","article-title":"Update from the advisory committee on immunization practices","volume":"8","author":"O'leary","year":"2019","journal-title":"J.\u00a0Pediatr. Infect. Dis. Soc."},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib131","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nmd.2020.02.001","article-title":"ENMC workshop study group. 242nd ENMC International Workshop: diagnosis and management of juvenile myasthenia gravis Hoofddorp, The Netherlands, 1-3 March 2019","volume":"30","author":"Munot","year":"2020","journal-title":"Neuromuscul. Disord."},{"issue":"2","key":"10.1016\/j.ejpn.2021.12.014_bib133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflamm atory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.ejpn.2021.12.014_bib134","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/mus.25628","article-title":"Infections and vaccinations as possible triggers of inflammatory myopathies","volume":"56","author":"Limaye","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/mus.25467","article-title":"Childhood macrophagic myofasciitis: a series from the Indian subcontinent","volume":"56","author":"Kakkar","year":"2017","journal-title":"Muscle Nerve"},{"issue":"13","key":"10.1016\/j.ejpn.2021.12.014_bib136","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/0961203309345734","article-title":"Vaccines as a trigger for myopathies","volume":"18","author":"Orbach","year":"2009","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3899\/jrheum.110721","article-title":"Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease","volume":"39","author":"Aikawa","year":"2012","journal-title":"J.\u00a0Rheumatol."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib138","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00296-007-0485-4","article-title":"HBV vaccine and dermatomyositis: is there an association?","volume":"28","author":"Altman","year":"2008","journal-title":"Rheumatol. Int."},{"issue":"6","key":"10.1016\/j.ejpn.2021.12.014_bib139","first-page":"13","article-title":"Rare complication of hepatitis B vaccination. An unusual cause of toxic shock syndrome","volume":"95","author":"Ram\u00edrez-Rivera","year":"2003","journal-title":"Bol. Asoc. Med. P. R."},{"issue":"17","key":"10.1016\/j.ejpn.2021.12.014_bib140","first-page":"675","article-title":"Dermatomiositis juvenil coincidiendo con la vacunaci\u00f3n de la hepatitis B [Juvenile dermatomyositis concomitant with hepatitis B vaccination]","volume":"111","author":"Fern\u00e1ndez-F\u00fanez","year":"1998","journal-title":"Med. Clin."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib141","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.autrev.2013.08.005","article-title":"A\u00a0review on the association between inflammatory myopathies and vaccination","volume":"13","author":"St\u00fcbgen","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.ejpn.2021.12.014_bib142","first-page":"583","article-title":"Influenza A H1N1\/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy","volume":"30","author":"Guissa","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib143","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3899\/jrheum.130246","article-title":"Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis","volume":"40","author":"Heijstek","year":"2013","journal-title":"J.\u00a0Rheumatol."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib144","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12969-020-00479-w","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study","volume":"18","author":"Grein","year":"2020","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"1","key":"10.1016\/j.ejpn.2021.12.014_bib145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects","volume":"76","author":"Caplan","year":"2017","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.ejpn.2021.12.014_bib146","first-page":"589","article-title":"Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy","volume":"19","author":"Kanakoudi-Tsakalidou","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejpn.2021.12.014_bib147","author":"Chatham"},{"issue":"7","key":"10.1016\/j.ejpn.2021.12.014_bib148","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/acr.20183","article-title":"Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids","volume":"62","author":"Pileggi","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"9","key":"10.1016\/j.ejpn.2021.12.014_bib149","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1080\/21645515.2015.1009337","article-title":"A\u00a0literature review on the patients with autoimmune diseases following vaccination against infections","volume":"11","author":"Liang","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejpn.2021.12.014_bib150","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm. Rep. (Morb. Mortal. Wkly. Rep.)"},{"issue":"3","key":"10.1016\/j.ejpn.2021.12.014_bib151","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/08830185.2010.483028","article-title":"Are anti-infectious vaccinations safe and effective in patients with autoimmunity?","volume":"29","author":"Salemi","year":"2010","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.ejpn.2021.12.014_bib152","first-page":"e80","article-title":"The state of vaccine safety science: systematic reviews of the evidence Lancet","volume":"20","author":"Dudley","year":"2020","journal-title":"Inf. Disp."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821002348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379821002348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:40:40Z","timestamp":1761072040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379821002348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":145,"alternative-id":["S1090379821002348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.12.014","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}